Fresenius Reports Strong Q3 2026 Results, Accelerates Biopharma Growth Strategy and Raises Full-Year Earnings Outlook
Fresenius has reported another strong financial performance for the third quarter of 2026, demonstrating continued progress in its #FutureFresenius transformation strategy. The company delivered healthy organic revenue growth, double-digit increases in operating earnings and core earnings per share, while further strengthening its profitability and return on invested capital. Supported by improved operational performance across its healthcare businesses, Fresenius is raising its full-year earnings expectations and accelerating investments in its strategic growth areas, particularly biopharmaceuticals.
During the third quarter, Fresenius benefited from consistent contributions from both of its major business divisions, Fresenius Kabi and Fresenius Helios. The company’s focus on operational improvements, financial discipline, portfolio development and innovation continued to support its performance despite ongoing macroeconomic uncertainty and changing conditions across the global healthcare industry.
Fresenius reported group revenue of €5.803 billion in the third quarter, representing organic growth of 5%. Both Fresenius Kabi and Fresenius Helios contributed to the increase, reflecting continued demand for healthcare products and services across the company’s international markets.
Group earnings before interest and taxes (EBIT), before special items, reached €638 million, increasing 10% at constant currency. The improvement was supported by strong contributions from Fresenius Kabi’s strategic Growth Vectors and continued earnings growth at Fresenius Helios. The Group’s EBIT margin also expanded by 50 basis points year over year to 11.0%, highlighting the company’s continued progress in strengthening operational efficiency and profitability.
Core earnings per share (Core EPS) increased by 14% at constant currency to €0.72. The improvement reflected strong operating performance across the business and lower interest expenses resulting from Fresenius’ continued efforts to reduce debt. Core net income also increased by 14% at constant currency to €403 million.
The company’s financial performance has allowed management to improve its full-year 2026 outlook. Fresenius now expects Core EPS growth to reach the upper half of its previously communicated range of 10% to 15% at constant currency. The company has also raised its Group EBIT margin expectation to above 11.5%, compared with its earlier indication of approximately 11.5%.
Return on invested capital (ROIC) reached 7.0%, moving further within the company’s long-term financial ambition range of 6% to 8%. This represents its highest ROIC level in a decade and reflects the impact of improved profitability, disciplined capital allocation and the structural changes introduced through the #FutureFresenius transformation.
Fresenius reported a net debt-to-EBITDA ratio of 2.5 times, including an approximately 20-basis-point impact associated with the mAbxience transaction. The company’s improved financial position provides additional flexibility to pursue strategic investments and expand its healthcare and biopharmaceutical businesses.
CEO Highlights Strong Execution and Strategic Progress
Michael Sen, Chief Executive Officer of Fresenius, said the company’s third-quarter results demonstrate the strength and consistency of its business execution. He highlighted the company’s organic revenue growth of 5%, alongside increases of 10% in EBIT and 14% in Core EPS at constant currency.
According to Sen, improvements in margins and returns demonstrate that Fresenius’ transformation strategy is delivering measurable financial benefits. The company has continued to strengthen its core operations while improving earnings visibility and creating additional opportunities for sustainable growth.
Sen also highlighted the performance of Fresenius Kabi’s Growth Vectors, which delivered 9% organic growth during the quarter. Biopharma was a particularly strong contributor, recording organic growth of 29%. The performance reflects the company’s increasing focus on innovative medicines, biosimilars and healthcare technologies.
Fresenius Helios also delivered strong growth and improved profitability, supported by solid revenue development and continued operational improvements across its hospital network.
The CEO emphasized that Fresenius is moving forward with its #FutureFresenius transformation through disciplined investments and strategic partnerships. These initiatives include the acquisition of the remaining 45% stake in mAbxience and a strategic development agreement with WuXi Biologics. Both initiatives are intended to strengthen the company’s biopharmaceutical capabilities and accelerate the development of its biosimilars portfolio.
Sen added that the company has strengthened its financial foundation and improved its ability to pursue innovation-led growth. Fresenius intends to build on its operational achievements while creating sustainable long-term value.
Fresenius Expands Biosimilars Pipeline Through Strategic WuXi Biologics Agreement
A significant development during the quarter was Fresenius’ announcement of an exclusive development agreement with WuXi Biologics on November 2, 2026. The agreement represents a major expansion of Fresenius’ biopharmaceutical strategy and is described by the company as the largest development agreement announced in the biosimilars industry to date.
Under the agreement, Fresenius will receive exclusive access to as many as 37 potential first-to-market biosimilar candidates. The collaboration is expected to significantly expand the company’s existing portfolio, which currently includes 29 marketed and pipeline molecules.
With the additional candidates, Fresenius aims to increase its biosimilars portfolio to as many as 66 molecules over the next decade. The expanded pipeline will target originator products representing more than €370 billion in sales, providing substantial long-term development opportunities in the global biopharmaceutical market.
Biosimilars are highly similar versions of already approved biological medicines. They can help expand treatment access, increase competition and provide additional options for healthcare systems managing the cost of complex therapies. As healthcare organizations continue to seek sustainable approaches to pharmaceutical spending, biosimilars are becoming an increasingly important part of the global medicines market.
The agreement with WuXi Biologics will provide Fresenius with greater flexibility to identify and advance development candidates based on its strategic priorities. Fresenius will retain full strategic flexibility in selecting which biosimilar candidates to develop and will maintain the full commercialization economics of products developed under the agreement.
Another important feature of the collaboration is the flexibility surrounding manufacturing. Fresenius will determine the long-term manufacturing strategy for each selected candidate and may use the mAbxience manufacturing network where appropriate.
This arrangement is expected to support the company’s ability to scale production while maintaining control over important commercial and operational decisions.
The expanded portfolio will cover 13 therapeutic areas and include multiple biological technologies. These technologies include monoclonal antibodies, bispecific antibodies, antibody-drug conjugates and fusion proteins.
The addition of these technologies will allow Fresenius to pursue opportunities across a broader range of complex biological medicines. It also strengthens the company’s position in an increasingly competitive biopharmaceutical environment.
The agreement is expected to accelerate Fresenius’ biosimilars development pipeline and support its longer-term growth ambitions beyond 2030. By combining external development capabilities with its own commercial and manufacturing expertise, Fresenius aims to establish a broader and more competitive portfolio of biosimilar medicines.
Fresenius Kabi Growth Vectors Continue to Drive Business Performance
Fresenius Kabi remained an important contributor to the Group’s third-quarter financial performance. Its strategic Growth Vectors, comprising Biopharma, MedTech and Nutrition, continued to gain market share and support organic growth.
The Growth Vectors delivered 9% organic revenue growth during the quarter, with Biopharma leading the performance at 29% organic growth.
The company’s focus on these business areas reflects its strategy of expanding beyond traditional healthcare products and investing in specialized medical technologies, nutritional products and biopharmaceutical treatments.
For the full year 2026, Fresenius Kabi expects organic revenue growth in the mid- to high-single-digit percentage range. Its EBIT margin is expected to reach the upper end of the previously communicated range of 16.5% to 17.0%.
These expectations reflect management’s confidence in the continued performance of its strategic growth businesses and its ability to maintain operational discipline.
Fresenius Helios Maintains Strong Growth and Profitability
Fresenius Helios also delivered a positive performance during the third quarter, supported by solid revenue growth, improvements in cost management and favorable operational developments.
Despite the usual seasonal patterns affecting hospital operations, the division achieved strong EBIT growth and contributed to the Group’s improved profitability.
The performance was supported by continued improvements in hospital operations and the effects of the surcharge on invoices for publicly insured patients in Germany. The related amounts were recognized under other operating income. This surcharge expired at the end of October 2026, while positive timing and phasing effects also supported the quarterly results.
Fresenius Helios continues to focus on operational efficiency, cost management and the delivery of high-quality hospital services. These efforts remain important as healthcare providers face increasing pressure from operating costs, workforce requirements and changing patient demand.
For the full year 2026, Fresenius Helios expects organic revenue growth in the mid-single-digit percentage range. The division continues to expect an EBIT margin between 10.0% and 10.5%.
Full-Year 2026 Financial Guidance Improved
Following its strong third-quarter performance, Fresenius has improved its full-year 2026 Core EPS outlook and raised its Group EBIT margin indication.
The company now expects Core EPS growth to reach the upper half of its previously announced 10% to 15% range at constant currency. The Group also expects its EBIT margin to exceed 11.5%.
Fresenius continues to expect organic Group revenue growth between 4% and 7% for the full year.
The updated guidance reflects management’s confidence in the company’s operating performance, improving financial position and continued progress across its strategic business areas.
The revised financial expectations are based on the following business outlook:
- Fresenius Group: Organic revenue growth of 4% to 7%, Core EPS growth reaching the upper half of the 10% to 15% range at constant currency, and an EBIT margin above 11.5%.
- Fresenius Kabi: Organic revenue growth in the mid- to high-single-digit percentage range, with an EBIT margin expected at the upper end of the 16.5% to 17.0% range.
- Fresenius Helios: Organic revenue growth in the mid-single-digit percentage range, with an EBIT margin expected between 10.0% and 10.5%.
The company noted that its guidance continues to reflect the uncertainty associated with the rapidly changing macroeconomic and geopolitical environment. These conditions may create additional volatility and operational challenges for businesses across the healthcare industry.
Fresenius also clarified that its current financial outlook does not include potential extreme scenarios that could significantly affect the company, its competitors or the broader healthcare sector.
Financial Discipline Supports Long-Term Growth Strategy
Fresenius’ latest results demonstrate the company’s continued emphasis on improving profitability while strengthening its financial position.
The reduction in interest expenses has become an important contributor to earnings growth. Continued debt reduction has allowed the company to benefit from a more favorable financial structure, supporting improvements in Core EPS and providing greater flexibility for strategic investments.
The Group’s net debt-to-EBITDA ratio stood at 2.5 times in the third quarter, including the impact associated with the mAbxience transaction.
Meanwhile, the increase in ROIC to 7.0% represents an important milestone in the company’s financial transformation. Reaching its highest level in a decade, the figure demonstrates progress toward the company’s long-term objective of maintaining returns within the 6% to 8% ambition range.
These financial improvements are particularly important as Fresenius expands its investments in biopharmaceutical development, biosimilars and other strategic growth businesses.
The company’s approach combines operational efficiency, financial discipline and targeted investment in areas that offer opportunities for sustainable healthcare growth.
#FutureFresenius Transformation Creates Opportunities for the Next Growth Phase
The third-quarter performance highlights the progress Fresenius has made through its #FutureFresenius transformation. The strategy focuses on strengthening the company’s core operations, improving financial performance, simplifying business structures and creating additional opportunities for innovation-led growth.
The company’s two major divisions, Fresenius Kabi and Fresenius Helios, continue to provide a strong operational foundation. At the same time, the expansion of Biopharma, MedTech and Nutrition creates opportunities to increase the contribution of specialized healthcare businesses.
The agreement with WuXi Biologics represents an important step in this direction. Access to as many as 37 additional biosimilar development candidates could significantly broaden Fresenius’ product pipeline and strengthen its long-term position in the global biopharmaceutical market.
The mAbxience transaction further supports this strategy by providing additional manufacturing and development capabilities.
As Fresenius moves into the next phase of its transformation, the company intends to maintain its focus on profitable growth, operational excellence and disciplined capital allocation.
Overall, the third-quarter 2026 results demonstrate continued improvements across revenue, operating earnings, margins and returns. With stronger financial performance, an improved full-year earnings outlook and an expanding biosimilars pipeline, Fresenius is positioning itself for its next stage of growth.
The company’s strategy is increasingly focused on combining a strengthened healthcare core with investments in innovative medicines and technologies. Through these initiatives, Fresenius aims to improve its competitive position, expand access to healthcare solutions and deliver sustainable long-term value.
Source link: https://www.fresenius.com/
